Quanterix, a company developing technology designed to enable earlier disease detection, made its market debut on Thursday. Shares of the company surged after pricing at $15 a share, and opening at $16.25 a share. Kevin Hrusovsky, CEO of Quanterix, was with us to discuss how the company plans to revolutionize healthcare.
The fourth-leading cause of death is drug side effects, and drugs only work half the time, says Hrusovsky. He believes that if you can personalize the drugs, you have an opportunity to improve the whole pharmaceutical industry.
Quanterix is developing technology that will digitize how they see into blood, and help to see disease long before there are symptoms. Rocket science is being deployed into the blood, says Hrusovsky. He says that if you can see biomarkers and incorporate into fitbits, it can really help improve health.
A look back on the hits and misses from last year's crystal ball on business, tech, politics, and culture.
Over the course of months of investigation into the illness, local authorities in partnership with CDC have narrowed in on a cause for the vaping illness that has sickened 2,506 and killed 54: thickening agent vitamin E acetate.
These are the headlines you Need 2 Know for Monday, December 23, 2019.
A look back on the decade.
Boeing's new Starliner capsule went off course after launch Friday and won't dock with the International Space Station during its first test flight.
These are the headlines you Need 2 Know for Thursday, December 19, 2019.
These are the headlines you Need 2 Know for Wednesday, December 18, 2019.
These are the headlines you Need 2 Know for Tuesday, December 17, 2019.
Pharmaceutical giant Allergan got FDA approval in 1989 to use Botulinum toxin for clinical use, representing a medical breakthrough: the first time microbial bacteria was approved for injection into the human body.
CEO Roei Ganzarski said the excitement of the moment the first electric-powered commercial flight took off felt like the birth of another child.
